Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerPharmacological TreatmentsComplications
Resumen de Investigación
Analyzed using Evidence Intelligence™
Empagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetes
Última actualización 11 de junio de 2026
Key finding
Empagliflozin group - Placebo group: -0.3643, 95% CI: -0.7571 to 0.0285, p=0.0686
This study tested the SGLT2 inhibitor empagliflozin in 79 people with type 2 diabetes and early kidney disease over 24 weeks. While empagliflozin showed early improvements in albumin excretion at 4 and 12 weeks, the difference was not significant by 24 weeks. However, it did reduce certain hypoxia-related proteins in the blood that may contribute to kidney damage.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Randomized Controlled Trial
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study tested the SGLT2 inhibitor empagliflozin in 79 people with type 2 diabetes and early kidney disease over 24 weeks. While empagliflozin showed early improvements in albumin excretion at 4 and 12 weeks, the difference was not significant by 24 weeks. However, it did reduce certain hypoxia-related proteins in the blood that may contribute to kidney damage.
Clinical relevance
Early diabetic kidney disease is a leading cause of kidney failure and cardiovascular disease. Understanding how SGLT2 inhibitors protect kidneys beyond glucose control is important for optimizing treatment strategies. This study suggests that empagliflozin may work partly by reducing hypoxia-induced proteins that promote abnormal blood vessel growth and kidney scarring, offering insight into the mechanisms behind the kidney-protective effects observed in larger clinical trials like EMPA-KIDNEY.
Keep in mind
Small sample size (79 participants) may have limited statistical power to detect ACR reduction Relatively short duration (24 weeks) may not capture long-term kidney protection effects Single spot urine test for ACR rather than standard three-day measurement increases biological variability Biomarkers measured in blood may not fully represent kidney tissue activity
Efectos Principales
↓ Serum VEGF (vascular endothelial growth factor)
↓ Serum ANGPTL2 (angiopoietin-like protein 2)
↔ Urinary albumin-to-creatinine ratio (trend toward reduction, not significant at 24 weeks)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Serum ANGPTL2, Serum ANGPTL4, Serum VEGF, and 3 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Serum ANGPTL2
- Serum ANGPTL4
- Serum VEGF
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
6
Evidence pairs
167
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
SGLT2 Inhibitors and Kidney Function
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and Adipokine and Angiogenic Markers
Guardar evidencia
Tema de evidencia
Diabetic Kidney Disease
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerUrinary albumin-to-creatinine ratio
Empagliflozin → Urinary albumin-to-creatinine ratio
Empagliflozin → Urinary albumin-to-creatinine ratio
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Tener en Cuenta
- Small sample size (79 participants) may have limited statistical power to detect ACR reduction Relatively short duration (24 weeks) may not capture long-term kidney protection effects Single spot urine test for ACR rather than standard three-day measurement increases biological variability Biomarkers measured in blood may not fully represent kidney tissue activity
Entre Líneas
- Small sample size (79 participants) may have limited statistical power to detect ACR reduction Relatively short duration (24 weeks) may not capture long-term kidney protection effects Single spot urine test for ACR rather than standard three-day measurement increases biological variability Biomarkers measured in blood may not fully represent kidney tissue activity
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Kidney Function, SGLT2 Inhibitors and Serum adrenomedullin.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → Kidney Function
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
SGLT2 Inhibitors → Serum adrenomedullin
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Kidney Function Evidence Hub
All studies measuring Kidney Function
2 studies
outcome_hubMeasures Kidney Function as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
2 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Serum adrenomedullin Evidence Hub
All studies measuring Serum adrenomedullin
1 studies
outcome_hubMeasures Serum adrenomedullin as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and Urinary albumin-to-creatinine ratio
Intervention: EmpagliflozinOutcome: Urinary albumin-to-creatinine ratio
2 results
All studies on Empagliflozin and Serum adrenomedullin
Intervention: EmpagliflozinOutcome: Serum adrenomedullin
1 results
All studies on Empagliflozin
Intervention: Empagliflozin
2 results
All studies measuring Urinary albumin-to-creatinine ratio
Outcome: Urinary albumin-to-creatinine ratio
2 results
All studies measuring Serum adrenomedullin
Outcome: Serum adrenomedullin
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve kidney function?
Strong Evidence
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Urinary albumin-to-creatinine ratio
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve adipokine and angiogenic markers?
Strong Evidence
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Serum ANGPTL2
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Serum VEGF
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 3
Serum ANGPTL4
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Empagliflozin improve serum adrenomedullin?
Emerging Evidence
Empagliflozin may improve Serum adrenomedullin.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Serum adrenomedullin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Empagliflozin improve urinary l-fabp?
Emerging Evidence
Empagliflozin may improve Urinary L-FABP.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Urinary L-FABP
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Empagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin reduces liver fat in diabetes patientsEmpagliflozin improves glycemic control in HNF1A-MODYEmpagliflozin improves glycemic control in type 1 diabetes patients
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.